AZN

AstraZeneca PLC American Depositary Shares New York Stock Exchange
$58.35
Open: $58.47 High: $58.47 Low: $57.98 Close: $58.345
Range: 2021-06-19 - 2021-06-21
Volume: 2,457,192
Market: Open
Powered by Finage Stock APIDelayed data
AZN
AstraZeneca PLC American Depositary Shares 1 Francis Crick Avenue Cambridge , CB2 0AA http://www.astrazeneca.com
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.
  • CEO: Pascal Soriot
  • Employees: 61,100
  • Sector: Healthcare
  • Industry: Drug Manufacturers
AZN News
Latest news about the AZN
  • There's 'huge demand' to vaccinate the world amid COVID variant concerns: Doctor

    Moderna is planning to expand its production to make COVID-19 vaccine boosters. Osmosis Chief Medical Officer & Former Center for Disease Control and Prevention Epidemic Intelligence Officer Dr. Rishi Desai joins Yahoo Finance Live to discuss.

    View More →
  • AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU

    A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.

    View More →
  • Vaccitech chief confident of beating mRNA in cancer treatment

    The chief executive of Vaccitech, which owns the technology behind the Oxford/AstraZeneca Covid-19 vaccine, believes the platform is more likely to treat cancers successfully than new medicines based on mRNA. Bill Enright, who recently took Vaccitech public on the Nasdaq, said the adenovirus vector elicits a more complete immune response that could be used to tackle tumours. Vaccitech is entering trials to treat lung and prostate cancer this year, while rivals BioNTech and Moderna have been developing cancer medicines using mRNA.

    View More →
  • Brazil Deaths Reach 500,000; U.S. Shots to Taiwan: Virus Update

    (Bloomberg) -- Brazil reached 500,000 deaths from Covid-19 on Saturday, a toll second only to the U.S. As the milestone was officially passed, thousands protested in major cities against President Jair Bolsonaro and his handling of the pandemic.U.S infections have fallen to the level of the first lockdowns in March 2020, though President Joe Biden warned of a “deadly threat” from the highly-transmissible delta variant first found in India and now expected to become the dominant strain in the U.S

    View More →
  • CDC Says Delta Strain Likely to Dominate in U.S.: Virus Update

    (Bloomberg) -- President Joe Biden urged unvaccinated Americans to get inoculated, warning that a highly transmissible variant of the virus could cause more deaths. The delta variant first found in India and now spread widely in the U.K. is expected to become the dominant strain in the U.S., said Rochelle Walensky, director of the Centers for Disease Control and Prevention.Americans can pack bags for European vacations as the European Union lifts travel curbs for residents of the U.S. Non-essent

    View More →
  • German lab, J&J still hashing out details of COVID-19 vaccine clot collaboration

    A scientist investigating rare blood clots possibly linked to AstraZeneca's and Johnson & Johnson's COVID-19 vaccines has yet to start a planned collaboration with the U.S. company, he said, as talks over their research pact continue. Dr. Andreas Greinacher, a transfusion medicine expert at Germany's Greifswald University, has been studying clotting with low blood platelets in people who got AstraZeneca's vaccine. In April, when clotting developed in a few people who got J&J's shot, Greinacher announced his lab would work with the U.S. company to explore causes.

    View More →
  • Court Rules on EU and AstraZeneca Dispute Over Vaccine Supplies. Here’s the Verdict.

    The European Commission had taken AstraZeneca to court accusing it of failing to honor its contract to deliver Covid-19 vaccine doses.

    View More →
  • AstraZeneca declares victory in vaccine battle with Brussels

    AstraZeneca has claimed victory in its bitter legal spat with Brussels over jab supplies after a court ruled that it did not need to speed up vaccine deliveries. Judges in Brussels threw out European Commission demands for immediate delivery of hundreds of millions of AstraZeneca jabs on the grounds that the company was struggling with "unprecedented" difficulties. The FTSE 100 company said the court had ruled it needed to deliver just 80m doses of its Covid vaccine before the end of September.

    View More →
  • U.S. moves to fill gap in treatments for COVID, as Delta variant creates worrying spike in new cases in the U.K.

    The U.S. is planning to invest $3.2 billion to develop antivirals to treat COVID-19 and other viruses that have the potential to become pandemics, moving to fill the gap in treatments for such serious illnesses as Ebola, dengue, West Nile and Middle East respiratory syndrome.

    View More →
  • AstraZeneca says EU defeated in legal bid over vaccine supplies

    AstraZeneca , the British-Swedish pharmaceutical group and developer of the world's most used COVID-19 vaccine, had a positive outcome in a court case brought by the European Union over its contract to deliver vaccine to the bloc. The European Commission, the EU's executive body, had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. AstraZeneca said the judge ordered delivery of 80.2 million doses by 27 Septem

    View More →
  • Court Rules In Favor Of AstraZeneca Over Delay In COVID-19 Shot Deliveries

    AstraZeneca Plc (NASDAQ: AZN) claims victory in a court tussle with the European Union over allegations that the company was not producing shots fast enough, thus missing COVID-19 vaccine deliveries. The company had planned 120 million vaccine doses cumulatively by the end of June 2021 and 300 million doses by the end of September. AZN intends to deliver more than 70 million by the end of the month. A judge ordered delivery of 80.2M doses by the end of September. The judgment also acknowledged t

    View More →
  • AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer

    AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU. The company had said it could not immediately deliver to the EU doses from an Oxford Biomedica factory in Britain because it had to supply the United Kingdom first. The EU lawyer said the judge decided that that factory must be used for EU supplies.

    View More →
  • Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal

    AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.

    View More →
  • UPDATE 5-EU loses bid for speedier AstraZeneca vaccine deliveries

    The European Union on Friday lost its bid to speed up deliveries of AstraZeneca's COVID-19 vaccines, the first of its legal challenges against the drugmaker that rocked the bloc as it scrambled to shore up supplies. AstraZeneca said the EU had lost its legal case, but European Commission President Ursula von der Leyen said the court ruling supported its view that the Anglo-Swedish pharmaceutical giant had failed to honour its commitments. The row plunged the EU into crisis earlier this year as states, under pressure to speed up vaccinations, scrambled for shots.

    View More →
  • AstraZeneca says EU loses legal bid for more vaccine supplies by end-June

    AstraZeneca on Friday said the European Union had lost a legal case against the pharmaceutical firm over the supply of COVID-19 vaccines as a court in Brussels rejected an EU request for more deliveries by the end of June. The Anglo-Swedish firm committed in a contract to do its best to deliver to the 27-nation bloc 300 million doses by the end of June, but production problems led the pharmaceutical company to revise down its target to 100 million vaccines. The cuts in the supplies delayed the EU's vaccination drive in the first quarter of the year, when the bloc had initially bet on AstraZeneca to deliver the largest volume of jabs.

    View More →
  • AstraZeneca Slips As Judge Sets Timeline, Fine For Delayed Shots

    By Dhirendra Tripathi

    View More →
  • The Smartest Stocks to Buy With $100 Right Now

    Best of all, you don't need to have Warren Buffett's pocketbook to build wealth on Wall Street. The rise of commission-free trading platforms and the removal of minimum deposit amounts by most brokerages means $100 is more than enough to begin or further your trek to financial freedom. As you're about to see, healthcare stocks are a wise place to put your money to work.

    View More →
  • UPDATE 1-S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people

    Some 760,000 South Koreans who have received a first dose of AstraZeneca Plc's COVID-19 vaccine will be offered Pfizer Inc's vaccine as a second shot due to shipment delays by global vaccine sharing scheme COVAX, the government said. Several countries, including Canada and Spain, have already approved such dose-mixing mainly due to concerns about rare and potentially fatal blood clots linked to the AstraZeneca vaccine. A Spanish study found that giving a dose of the Pfizer shot to people who already received the AstraZeneca vaccine is highly safe and effective, according to preliminary results.

    View More →
  • S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people

    Some 760,000 South Koreans who have received a first dose of AstraZeneca Plc's COVID-19 vaccine will be offered Pfizer Inc's vaccine as a second shot due to shipment delays by global vaccine sharing scheme COVAX, the government said. Several countries, including Canada and Spain, have already approved such dose-mixing mainly due to concerns about rare and potentially fatal blood clots linked to the AstraZeneca vaccine. A Spanish study found that giving a dose of the Pfizer shot to people who already received the AstraZeneca vaccine is highly safe and effective, according to preliminary results.

    View More →
  • Vaccine cocktails cause headaches for Italy’s government

    Italian cocktails such as the Aperol Spritz are being enjoyed in many European capitals these sunny days, but mixing Covid-19 shots is proving a recipe with potentially toxic effects for the government of Mario Draghi. Sticking with toxic politics, an en masse resignation at the Oslo city council has highlighted the difficulties even respectable Nordic oil producing countries face in working out how to meet their international climate obligations. Eurogroup chief Paschal Donohoe, who has been trying to land a “work plan” setting out how to advance the complex initiative, said it would take more time to agree the plan between member states and that he would return to the matter later this year.

    View More →